Amarin’s (AMRN) Buy Rating Reaffirmed at Leerink Swann

Leerink Swann reaffirmed their buy rating on shares of Amarin (NASDAQ:AMRN) in a research report report published on Monday morning, TipRanks reports. They currently have a $29.00 target price on the biopharmaceutical company’s stock.

AMRN has been the topic of a number of other research reports. Jefferies Financial Group reiterated a buy rating and set a $30.00 price target on shares of Amarin in a research note on Friday. BidaskClub raised shares of Amarin from a sell rating to a hold rating in a report on Monday, October 21st. Oppenheimer started coverage on shares of Amarin in a report on Tuesday, November 19th. They set an underperform rating and a $7.00 price objective for the company. Cantor Fitzgerald reiterated a buy rating and set a $35.00 target price on shares of Amarin in a research report on Monday. Finally, Aegis started coverage on shares of Amarin in a research note on Thursday, October 31st. They issued a buy rating and a $23.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $27.08.

AMRN stock opened at $21.40 on Monday. The stock has a market capitalization of $7.60 billion, a price-to-earnings ratio of -54.87 and a beta of 1.14. The company has a 50-day moving average of $18.66 and a two-hundred day moving average of $17.71. Amarin has a 52-week low of $11.78 and a 52-week high of $24.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.69 and a quick ratio of 3.45.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Amarin had a negative return on equity of 26.67% and a negative net margin of 17.42%. The business had revenue of $112.40 million for the quarter, compared to analyst estimates of $110.04 million. During the same period in the previous year, the company posted ($0.08) earnings per share. The firm’s revenue for the quarter was up 104.4% on a year-over-year basis. Equities analysts expect that Amarin will post -0.13 EPS for the current fiscal year.

In related news, Director Lars Ekman sold 38,600 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $24.02, for a total transaction of $927,172.00. Also, CEO John F. Thero sold 475,546 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $24.02, for a total transaction of $11,422,614.92. Insiders have sold 788,600 shares of company stock worth $18,088,620 in the last 90 days. Company insiders own 2.75% of the company’s stock.

Several large investors have recently bought and sold shares of AMRN. Oppenheimer & Co. Inc. lifted its stake in Amarin by 19.7% in the third quarter. Oppenheimer & Co. Inc. now owns 27,779 shares of the biopharmaceutical company’s stock valued at $421,000 after buying an additional 4,570 shares during the period. Invesco Ltd. increased its holdings in shares of Amarin by 1,402.6% in the second quarter. Invesco Ltd. now owns 8,414,943 shares of the biopharmaceutical company’s stock worth $163,166,000 after acquiring an additional 7,854,902 shares in the last quarter. Bank of America Corp DE raised its position in shares of Amarin by 73.3% during the second quarter. Bank of America Corp DE now owns 404,748 shares of the biopharmaceutical company’s stock worth $7,849,000 after purchasing an additional 171,136 shares during the period. Parallel Advisors LLC boosted its position in Amarin by 9,893.5% during the 3rd quarter. Parallel Advisors LLC now owns 19,987 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 19,787 shares during the last quarter. Finally, Carlson Capital L P lifted its position in shares of Amarin by 13.6% in the second quarter. Carlson Capital L P now owns 265,000 shares of the biopharmaceutical company’s stock worth $5,138,000 after purchasing an additional 31,625 shares in the last quarter. Institutional investors and hedge funds own 52.87% of the company’s stock.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

See Also: Understanding dividend yield and dividend payout ratio

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.